HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors

Authors: Chiara Liverani, Chiara Spadazzi, Toni Ibrahim, Federica Pieri, Flavia Foca, Chiara Calabrese, Alessandro De Vita, Giacomo Miserocchi, Claudia Cocchi, Silvia Vanni, Giorgio Ercolani, Davide Cavaliere, Nicoletta Ranallo, Elisa Chiadini, Giovanna Prisinzano, Stefano Severi, Maddalena Sansovini, Giovanni Martinelli, Alberto Bongiovanni, Laura Mercatali

Source: Frontiers in Endocrinology, Vol 13 (2023)

Subject Terms: nen, primary cultures, Lenvatinib efficacy, HRAS overexpression, predictive marker, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fendo.2022.1045038/full; https://doaj.org/toc/1664-2392

Access URL: https://doaj.org/article/6702750d458546d594d1121a5c66b84f